Suresh M. Solapure

Bellary Road
Bengaluru, KA 560024, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Journal: Antimicrobial agents and chemotherapy

Published: October 26, 2018

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Journal: Antimicrobial agents and chemotherapy

Published: January 23, 2018

Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.

Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.

Journal: Journal of medicinal chemistry

Published: January 12, 2017

Evaluation of the metabolism, bioactivation and pharmacokinetics of triaminopyrimidine analogs toward selection of a potential candidate for antimalarial therapy.

Evaluation of the metabolism, bioactivation and pharmacokinetics of triaminopyrimidine analogs toward selection of a potential candidate for antimalarial therapy.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: October 19, 2016

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.

Journal: Science translational medicine

Published: December 01, 2015

In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment.

In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment.

Journal: Antimicrobial agents and chemotherapy

Published: December 26, 2014

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.

Journal: Nature communications

Published: September 15, 2014

1,4-azaindole, a potential drug candidate for treatment of tuberculosis.

1,4-azaindole, a potential drug candidate for treatment of tuberculosis.

Journal: Antimicrobial agents and chemotherapy

Published: June 25, 2014

Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.

Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.

Journal: ACS medicinal chemistry letters

Published: May 19, 2014

Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis.

Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis.

Journal: Antimicrobial agents and chemotherapy

Published: May 14, 2014

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.

Journal: Journal of medicinal chemistry

Published: May 09, 2014

Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.

Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.

Journal: Journal of medicinal chemistry

Published: November 13, 2013

Showing 1-12 of 18

Last Updated: 09/26/2026